Weak stock price reactionRemoving the threat of a nasty dilutive offering should have caused the stock price to jump considerably today. While the day is not over, it is clear no one is paying attention to what TH is up to by the low trading volume. Hopefully, this will highlight to management the enormity of their task to get THTX treated like most other small biotechs. When Paul first suggested a debt offering like this was a possibility he said a CEO friend of his at another biotech company saw their stock rise 30% or so on news of a similar offering.
The news today was very good, particularly in a very difficult biotech funding environment, but the stock's muted reaction shows few are paying any attention at all and that THTX still has a lot of distance to go to repair their relationships with investors.
Hopefully, we will get additional good news tomorrow but it is going to take more than good news to get a better value on the share price if few are paying any attention to it. Correcting that needs to be a top priority and good clinical results in cancer should help if they can achieve them.